Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133598) titled 'A Study on Whether Patients with iMCD Can Safely Stop TCP Treatment After Remission' on Sept. 29.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Peking Union Medical College Hospital
Condition:
Idiopathic multicentric Castleman disease (iMCD)
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-10-01
Target Sample Size: TCP Response Followed by Treatment Discontinuation in iMCD Patients:25;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=344977
Published by HT Digital Content Services with permission...